Meticulous Research®, a leading global market research company, published a research report titled, 'Europe Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Forecast to 2030.’
Download Free Sample Report@ https://www.meticulousresearch.com/download-sample-report/cp_id=5592?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=15-10-2024
According to the latest publication by Meticulous Research®, the Europe pharmaceutical contract development and manufacturing (CDMO) market is projected to reach $68.12 billion by 2030, growing at a CAGR of 7.4% between 2024 and 2030. This growth is driven by several factors, including the increasing prevalence of chronic diseases, rising health awareness, a growing elderly population, higher pharmaceutical R&D spending, cost-effective manufacturing solutions, increased government support for drug development, improvements in healthcare infrastructure, and rising healthcare expenditures.
However, the market faces challenges such as a shortage of skilled professionals. Nonetheless, opportunities for growth exist, particularly in the high demand for personalized medicine, cell and gene therapies, as well as advancements in high potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) within European countries.
Key Players
Prominent companies in the European pharmaceutical CDMO market include AbbVie Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter Pharma International GmbH (Germany), Catalent, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), Boehringer Ingelheim (Germany), Eurofins Scientific (France), Curia Global, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), Fabbrica Italiana Sintetici S.p.A. (Italy), and Corden Pharma GmbH (Germany).
Market Segmentation and Outlook
The Europe pharmaceutical CDMO market is segmented by service type, end user, and geography. By service type, the market includes pharmaceutical manufacturing services (Active Pharmaceutical Ingredient (API) manufacturing and Finished Dosage Forms (FDF) manufacturing), drug development services, and biologics manufacturing services. In 2024, pharmaceutical manufacturing services are expected to dominate, driven by the need for cost-efficient manufacturing, high-quality bulk production, and the growing demand for generic drugs.
In terms of end users, generic pharmaceutical companies are expected to see the highest growth rate, as competition in the generic market intensifies and companies increasingly turn to contract manufacturing to adopt cutting-edge technologies and reduce costs.
Geographic Overview
The report covers key European markets such as Germany, the U.K., France, Italy, Spain, Switzerland, the Netherlands, Denmark, and the Rest of Europe. Germany is anticipated to hold the largest market share in 2024, given its status as a leading exporter of medicinal products and a top pharmaceutical producer globally. The country’s focus on personalized medicine and biopharmaceuticals is expected to drive demand for CDMO services.
In response to rising demand, CDMOs in Germany are expanding their facilities. For instance, in July 2021, Richter-Helm Biologics GmbH & Co. KG opened a new production facility in Bovenau, Germany, significantly increasing its biopharmaceutical manufacturing capacity.
Conclusion
The Europe pharmaceutical CDMO market is poised for substantial growth over the coming years. While challenges like skill shortages and competition exist, opportunities driven by innovations in personalized medicine, biologics, and increased demand for cost-effective manufacturing solutions present a promising future for the sector. Strategic partnerships and technological advancements will be crucial for companies aiming to establish a strong market presence.
About Meticulous Research®:
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments on “European Pharma CDMO Industry Poised for $68.12 Billion by 2030”